<bill session="118" type="s" number="150" updated="2025-07-21T19:32:26Z">
  <state datetime="2024-07-11">PASS_OVER:SENATE</state>
  <status>
    <unknown datetime="2024-07-11"/>
  </status>
  <introduced datetime="2023-01-30"/>
  <titles>
    <title type="display">Affordable Prescriptions for Patients Act of 2023</title>
    <title type="short" as="reported to senate">Affordable Prescriptions for Patients Act of 2023</title>
    <title type="short" as="introduced">Affordable Prescriptions for Patients Act of 2023</title>
    <title type="short" as="passed senate">Affordable Prescriptions for Patients Act of 2023</title>
    <title type="official" as="introduced">A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="C001056"/>
  <cosponsors>
    <cosponsor bioguide_id="B001277" joined="2023-01-30"/>
    <cosponsor bioguide_id="B001310" joined="2023-05-02"/>
    <cosponsor bioguide_id="C001098" joined="2023-01-30"/>
    <cosponsor bioguide_id="D000563" joined="2023-01-30"/>
    <cosponsor bioguide_id="G000386" joined="2023-01-30"/>
    <cosponsor bioguide_id="K000367" joined="2023-01-30"/>
    <cosponsor bioguide_id="M001153" joined="2024-04-09"/>
    <cosponsor bioguide_id="W000800" joined="2023-05-02"/>
  </cosponsors>
  <actions>
    <action datetime="2023-01-30">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2023-01-30" state="REFERRED">
      <text>Read twice and referred to the Committee on the Judiciary.</text>
    </action>
    <action datetime="2023-02-09" state="REPORTED">
      <text>Committee on the Judiciary. Ordered to be reported without amendment favorably.</text>
    </action>
    <action datetime="2023-03-01">
      <text>Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.</text>
    </action>
    <calendar datetime="2023-03-01" calendar="Senate Legislative" under="General Orders" number="22">
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.</text>
    </calendar>
    <action datetime="2024-07-11">
      <text>Measure laid before Senate by unanimous consent.</text>
      <reference ref="CR S4537-4538" label="consideration"/>
    </action>
    <vote how="by Unanimous Consent" type="vote" datetime="2024-07-11" where="s" result="pass" state="PASS_OVER:SENATE">
      <text>Passed Senate with an amendment by Unanimous Consent.</text>
      <reference ref="CR S4537-4538" label="text of amendment in the nature of a substitute"/>
    </vote>
    <action datetime="2024-07-12">
      <text>Message on Senate action sent to the House.</text>
    </action>
    <action datetime="2024-07-15T14:02:01-04:00">
      <text>Received in the House.</text>
    </action>
    <action datetime="2024-07-15T14:03:00-04:00">
      <text>Held at the desk.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSJU" name="Senate Judiciary" subcommittee="" activity="Reported By, Markup By, Referred To"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Civil actions and liability"/>
    <term name="Competition and antitrust"/>
    <term name="Consumer affairs"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Federal Trade Commission (FTC)"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Intellectual property"/>
    <term name="Judicial review and appeals"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments>
    <amendment number="s2399"/>
  </amendments>
  <summary date="2024-09-19T19:12:28Z" status="Passed Senate">Affordable Prescriptions for Patients Act of 2023 

This bill&#160;limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.

Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

&#160;

&#160;</summary>
</bill>
